Anondita Medicare Limited has scheduled an in-person meeting with a group of investors in Mumbai on July 11, 2026, to discuss business performance and strategy. The meeting, set to begin at 9:00 AM IST, will be conducted pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company confirmed that the discussions with investors and analysts will rely solely on generally available information. Management emphasized that the session will not involve any Unpublished Price Sensitive Information in accordance with the company's Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

The schedule for the meeting is subject to change due to exigencies on the part of the fund, broking house, or the company. Details regarding the event have been made available on the official website of Anondita Medicare Limited .

Investor Meet Details

Anondita Medicare Limited has secured in-principle approval from the National Stock Exchange of India Limited to issue 2,85,000 convertible equity share warrants on a preferential basis to the Promoter Category. The warrants, priced at ₹1,038 each with a face value of ₹10, will convert into fully paid-up equity shares, providing capital infusion for the company. This approval, granted via letter No. NSE/LIST/55045 dated June 25, 2026, is subject to the company fulfilling specific conditions set by the exchange.

The issuance is governed by Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Upon conversion, each warrant will entitle the holder to one equity share. The approval enables the company to proceed with the allotment after securing necessary statutory clearances from authorities including SEBI, RBI, and MCA.

The National Stock Exchange has outlined several conditions for the final allotment. The company must file the listing application promptly after allotment and ensure compliance with all applicable guidelines, regulations, and directions of the exchange and statutory authorities. Additionally, Anondita Medicare is required to pay applicable fees and submit any documents requested by the exchange.

Compliance and Monitoring Requirements

The exchange has emphasized the need for strengthened internal controls to monitor trades executed by the proposed allottees. Anondita Medicare must obtain an undertaking from allottees confirming they will not engage in intra-day trading or sell the company's scrip until the allotment date. The responsibility for verifying this compliance and ensuring adherence to Regulation 167(6) of SEBI ICDR Regulations, 2018, rests solely with the issuer company.

Failure to comply with these conditions could result in the withdrawal of the in-principle approval or impact the listing of the resultant shares. The exchange reserves the right to revoke the approval if any information provided is found to be incomplete, incorrect, misleading, or in contravention of regulations.

Key Details of the Warrant Issue